Research

Metabolic adaptation

Tirzepatide increases insulin secretion, reduces glucagon release, decreases fasting and postprandial glucose levels, promotes satiety, decreases body weight, and delays gastric emptying.

Tirzepatide can help manage blood sugar levels and weight in patients with type 2 diabetes.

StrongSupportsmedium confidence
Tirzepatide increases insulin secretion, reduces glucagon release in a glucose-dependent manner, decreases fasting and postprandial glucose levels, promotes satiety, decreases body weight, and delays gastric emptying.
Elaine Wong et al. · American Journal of Therapeutics · 2022

Why this rating

Supported by clinical trial data mentioned in the abstract.

Source

Tirzepatide: A Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus

Elaine Wong et al. · American Journal of Therapeutics · 2022

reviewCited 8×
Read the paper

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →